Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non‐small cell lung cancer
Ikuo Sekine(University of Tsukuba), Nagahiro Saijo(National Cancer Center Hospital East), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Manabu Tanaka(Saitama Children's Medical Center), Tetsuro Kodama, Fumihiro Oshita(Kanagawa Cancer Center), Hiroshi Nokihara(Tokushima University Hospital), Kosuke Yamashita(Kanagawa Prefectural Hospital Organization), Tomohide Tamura(St. Luke's International Hospital), Hideo Kunitoh(Japanese Red Cross Medical Center), Kouzou Yamada(Kanagawa Prefectural Hospital Organization), Kazumasa Noda, Yuichiro Ohe(National Cancer Center), Noboru Yamamoto(Tokyo National Hospital)
Cited by 38
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Metabolic gene polymorphism frequencies in control populations.
|PubMed|2001|847
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835